Protocol for the QuickSwitch Peptide Screening Assay
QuickSwitch™ Peptide Screening Assay Protocol
Validation of Neoantigen In Silico Prediction using QuickSwitch™ Kits
Research findings indicate that neoantigens have the potential to activate tumour-specific T-cell-mediated anti-tumour immune responses.
Human MHC Class II QuickSwitch™ Platform is used to Identify SARS-CoV-2 Virus Derived Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether that
How to Identify SARS-CoV-2 Virus Derived Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research), MBL International describes how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
Find Human MHC Class I Dominant Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
Comparing Theoretical Peptide-MHC Binding Affinity to Real Values produced by the QuickSwitch™ Platform
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
How to screen SARS-CoV-2 peptides to facilitate T cell research
Whenever our immune system is faced with a challenge, be it a multicellular parasite, a bacteria, a virus, or even cancer, this threat is detected and sampled primarily by the protein sequence of the pathogen in question. Other aspects of
White Paper: Analysis of neoantigen-reactive T cells using the QuickSwitch™ custom tetramer kit
Kazuhiro Kakimi MD, PhD has been a leader in developing effective immunotherapies against cancer for the last 15 years in Japan. In this whitepaper, he and his colleagues have reported that the QuickSwitch™ Custom Tetramers will become an essential tool
Evaluating the biological activity of a cancer vaccine with the HLA-A*02:01 QuickSwitch™ Quant platform
Principle of the cell-based T2 shift assay and the cell-free QuickSwitch™ Quant assay Comparison of the cell-based T2 shift assay and the cell-free QuickSwitch™ Quant assay Immuno-oncology is a growing field in which different strategies such as immune modulators, vaccines
High-Quality Stock and Custom Peptides
Suitable for Stimulation Assays High-Quality Control ≥95% Purity and Mass Spec Analysed Custom tetramer generation using QuickSwitch™ and QuickSwitch™ Quant Tetramer MBL International‘s stock and custom peptides can be used for stimulation assays along with custom tetramer generation using